TLC 388

Drug Profile

TLC 388

Alternative Names: Lipotecan; TLC-388; TLC388 HCl

Latest Information Update: 18 Jan 2016

Price : $50

At a glance

  • Originator Taiwan Liposome Company
  • Class Antineoplastics; Camptothecins
  • Mechanism of Action Angiogenesis inhibitors; DNA topoisomerase I inhibitors; Hedgehog protein inhibitors; Hypoxia-inducible factor 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatocellular carcinoma; Rectal cancer
  • No development reported Solid tumours
  • Discontinued Renal cell carcinoma

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 18 Jan 2016 Phase-II clinical trials in Rectal cancer in Taiwan (IV)
  • 01 Jun 2015 National Health Research Institutes plans a phase II trial for Neuroendocrine carcinoma in Taiwan (NCT02267213)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top